Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mead

Showing results (421-430 of 435) with videos related to

Pageof 44
Sort By:
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Nature Genetics|September 4, 2023
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolutionAlba Rodriguez-Meira, Ruggiero Norfo, Sean Wen, et al.
Science (New York, N.Y.)|August 14, 2025
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNALauren Murphy, Jeanne Inchauspé, Giampiero Valenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of <i>DYRK1A</i>C K Brierley, B H Yip, G Orlando, et al.
Leukemia|February 13, 2021
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasmRichard A Salisbury, Natalia Curto-Garcia, Jennifer O'Sullivan, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Science Translational Medicine|October 9, 2024
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axisRong Li, Michela Colombo, Guanlin Wang, et al.
Nature Genetics|June 9, 2025
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1ACharlotte K Brierley, Bon Ham Yip, Giulia Orlando, et al.
Blood|January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemiaJohn Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Pageof 44

Showing results (421-430 of 435) with videos related to

Sort By:
Pageof 44
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Nature Genetics|September 4, 2023
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolutionAlba Rodriguez-Meira, Ruggiero Norfo, Sean Wen, et al.
Science (New York, N.Y.)|August 14, 2025
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNALauren Murphy, Jeanne Inchauspé, Giampiero Valenzano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of <i>DYRK1A</i>C K Brierley, B H Yip, G Orlando, et al.
Leukemia|February 13, 2021
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasmRichard A Salisbury, Natalia Curto-Garcia, Jennifer O'Sullivan, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
Science Translational Medicine|October 9, 2024
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axisRong Li, Michela Colombo, Guanlin Wang, et al.
Nature Genetics|June 9, 2025
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1ACharlotte K Brierley, Bon Ham Yip, Giulia Orlando, et al.
Blood|January 10, 2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemiaJohn Mascarenhas, Heidi E Kosiorek, Josef T Prchal, et al.
Pageof 44